

TEMPLE-FIXED PEPTIDOMIMETICS AS MEDICAMENTS AGAINST HIV AND CANCER
 Application No. 10/550,778 Inventors: Zumbrunn et al. Docket No 753-54 PCT/US

REPLACEMENT SHEET

83

Table 1: Examples 1-6, n = 4, n' = 6

Example	Seq. ID	P6'	P5'	P4'	P3'	P2'	P1'	Template	P1	P2	P3	P4	RT	Purity% ^a [M+ H]/2	
1	SEQ ID NO:1	Arg	Arg	2-Nal	Cys	Tyr	Arg	D ₁ Lys ₂ Pro	Tyr	Cit	Cys	Arg-NH ₂	3.75	98	862.6
2	SEQ ID NO:2	Arg	Arg	2-Nal	Cys	Tyr	Lys	D ₁ Lys ₂ Pro	Tyr	Cit	Cys	Arg-NH ₂	3.87	96	876.3
3	SEQ ID NO 3	Arg	Arg	2-Nal	Cys	Tyr	Lys	D ₁ Lys ₂ Pro	Arg	Cit	Cys	Arg-NH ₂	3.28	97	858.4
4	SEQ ID NO 4	Arg	Arg	2-Nal	Cys	Tyr	Lys	D ₁ Pro ₂ Pro	Tyr	Arg	Cys	Arg-NH ₂	4.62	100	845.9
5	SEQ ID NO:5	Arg	Arg	2-Nal	Cys	Tyr	Arg	D ₁ Pro ₂ Pro	Tyr	Arg	Cys	Arg-NH ₂	4.83	98	860.0
6	SEQ ID NO:6	Arg	Arg	2-Nal	Cys	Tyr	Arg	L ₁ Lys ₂ Pro	Tyr	Cit	Cys	Arg-NH ₂	4.10	96	875.9

a) % purity of compounds after prep. HPLC.
 cysteines at position P3' and P3 are linked by a disulfide bridge